Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Amphion Innovations

Amphion Innovations develops and operates companies in the life sciences and medical technology sectors. Amphion works in partnership with universities and corporations seeking to commercialise intellectual property using its proven company creation and building process.

Portfolio performing well and revenues from IP

Unique process for commercialising IP Successful

20 year record; and NAV/share growth since IPO (2005) of 36% per annum ($), 28% (£)

Rigorous election process for investments, mitigating risk

Partner Companies performing well

Share price discount to reported NAV anomalous

Publication Date:
June 12 2008

Good results, but core strength is quality and value of portfolio

Revenues + 48%

NAV + 36%

Successful financings for Amphion and partner companies

Gulf initiative and IP entity formed

Shares trading barely above NAV gives significant potential upside

Publication Date:
September 18 2007

Amphion; Stock market still missing the point

  • Positive trading update
  • Strategic Gulf venture taps into rapidly growing market
  • Myconostica: another UK addition to portfolio
  • Significant realised gains on Beijing Med-Pharm
  • 20 years of high NAV growth delivered by management
  • Valued at a deep discount to peer group

Publication Date:
February 9 2007

Amphion; building a strong future

  • Development and investment in life sciences/medtech
  • Unique process for commercialising IP
  • Proven record of success over 20 years
  • Currently valued at deep discount to peer group (market cap/NAV multiple)

Publication Date:
March 13 2006